CFMS — ConforMIS Share Price
0.000.00%
Last trade - 00:00HealthcareSpeculativeMicro Cap
- $17.80m
- $12.26m
- $62.05m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.39 | ||
| Price to Tang. Book | 0.39 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.3 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -58.46% | ||
| Return on Equity | -67.39% | ||
| Operating Margin | -69.05% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 89.79 | 77.43 | 68.76 | 99.86 | 62.05 | 53.29 | 58.94 | -4.5% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Conformis, Inc. is a medical technology company. The Company is engaged in the development, manufacturing, and sales of patient-specific products and instrumentation that are individually sized and shaped to fit each patient's various knee and hip anatomy. The Company offers knee replacement products and knee replacement products. The Company's product portfolio is designed to maximize surgeon and patient choice by offering fully personalized solutions through its Image-to-Implant Platinum Services Program, as well as data-informed, standardized solutions that combine many benefits of personalization with an off-the-shelf system. Its sterile, just-in-time, Surgery-in-a-Box delivery system is available with all of its implants and personalized, single-use instruments. The Company owns or in-licenses issued patents and pending patent applications that cover personalized implants and patient-specific instrumentation for all major joints.
Directors
- Kenneth Fallon NEC (81)
- Mark Augusti PRE (55)
- Robert Howe CFO (51)
- Carrie Bienkowski IND (49)
- Philip Johnston IND (76)
- Bradley Langdale IND (56)
- Richard Meelia IND (72)
- Michael Milligan IND (57)
- Last Annual
- December 31st, 2022
- Last Interim
- March 31st, 2023
- Incorporated
- March 26th, 2004
- Public Since
- July 1st, 2015
- No. of Shareholders
- 143
- No. of Employees
- 295
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 7,878,332
- Address
- 600 Technology Drive, BILLERICA, 01821
- Web
- http://www.conformis.com/
- Phone
- +1 7813459001
- Auditors
- Grant Thornton LLP
Upcoming Events for CFMS
Conformis Inc Extraordinary Shareholders Meeting
Q3 2023 Conformis Inc Earnings Release
Similar to CFMS
Accelerate Diagnostics
NASDAQ Capital Market
Adapthealth
NASDAQ Capital Market
Aethlon Medical
NASDAQ Capital Market
Agendia NV
NASDAQ Capital Market
Akili
NASDAQ Capital Market
FAQ
What is the ConforMIS share price?
As of Today at 01:06 UTC, shares in ConforMIS are trading at $2.23. This share price information is delayed by 15 minutes.
How has the ConforMIS share price performed this year?
Shares in ConforMIS last closed at $2.23 and the price had moved by -68.48% over the past 365 days. In terms of relative price strength the ConforMIS share price has underperformed the S&P500 Index by -72.94% over the past year.
What are the analyst and broker recommendations for ConforMIS?
The overall consensus recommendation for ConforMIS is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the ConforMIS dividend yield?
ConforMIS does not currently pay a dividend.
Does ConforMIS pay a dividend?
ConforMIS does not currently pay a dividend.
When does ConforMIS next pay dividends?
ConforMIS does not currently pay a dividend.
How do I buy ConforMIS shares?
To buy shares in ConforMIS you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of ConforMIS?
As of the previous close price of $2.23, shares in ConforMIS had a market capitalisation of $17.57m.
Where are ConforMIS shares listed?
Here are the trading details for ConforMIS:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: CFMS
What kind of share is ConforMIS?
Based on an overall assessment of its quality, value and momentum ConforMIS is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a ConforMIS share price forecast for 2023?
The analyst consensus target price for shares in ConforMIS is $50.00. That is 2142.15% above the last closing price of $2.23.
Analysts covering ConforMIS currently have a consensus Earnings Per Share (EPS) forecast of -$5.21 for the next financial year.
Find out moreWhat is the trend in the ConforMIS share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like ConforMIS. Over the past six months, its share price has underperformed the S&P500 Index by -27.73%.
As of the last closing price of $2.23, shares in ConforMIS were trading +2.08% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the ConforMIS PE Ratio?
The ConforMIS PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.23.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of ConforMIS?
ConforMIS' management team is headed by:
- Kenneth Fallon - NEC
- Mark Augusti - PRE
- Robert Howe - CFO
- Carrie Bienkowski - IND
- Philip Johnston - IND
- Bradley Langdale - IND
- Richard Meelia - IND
- Michael Milligan - IND